Supreme Court Puts Brakes on Abortion Pill Restrictions

By Carmen Pope, Senior Editor, Drugs.com

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 5, 2026.

MONDAY, May 4, 2026 — The Supreme Court has temporarily stepped in to preserve nationwide access to the abortion pill mifepristone, halting a lower court ruling that would have made the medication significantly harder to obtain.

Justice Samuel Alito issued the temporary pause on Monday, keeping a recent appeals court decision on hold until at least May 11. The move buys time for the Supreme Court to weigh emergency requests from mifepristone manufacturers Danco and GenBioPro while the broader legal battle plays out.

What changed, and what it means for patients

For now, mifepristone can continue to be prescribed without an in-person doctor’s visit, meaning it can be mailed to patients anywhere in the country, including in states with strict abortion restrictions. That access had been thrown into uncertainty after a New Orleans appeals court sided with Louisiana’s request to reinstate an older requirement that patients meet with a doctor face-to-face before receiving the drug.

Planned Parenthood Action Fund president Alexis McGill Johnson welcomed the Supreme Court’s intervention, but noted that the rapid back-and-forth had already taken a toll. She said the instability had created real consequences for patients and healthcare providers trying to navigate the shifting legal landscape.

Background

The case centres on Covid-era rules made permanent by the Biden administration that allowed mifepristone to be dispensed without an in-person visit. Anti-abortion groups argue those rules should never have been made permanent. At the same time, the drug’s manufacturers contend that Louisiana lacks the legal standing to challenge them. The same argument that succeeded at the Supreme Court in 2024, when an earlier attempt to restrict the medication was rejected.

The FDA had separately requested the case be paused while it conducts its own safety review of mifepristone, commissioned by Health Secretary Robert F. Kennedy Jr. Reproductive health researchers have pushed back on the report that prompted the review, arguing it overstated the drug’s risks and was not subject to peer review or published in a medical journal. The medication has been found safe and effective in numerous studies.

The Supreme Court’s pause is temporary. Louisiana has been ordered to respond to the manufacturers’ emergency requests by Thursday, after which the court will determine the next steps.